Johnson & Johnson (JNJ)
87.21USD
23 May 2013
$-0.59 (-0.67%)
$88.46
$87.11
$87.97
$87.00
14,446,889
--
--
--
JNJ
About
Overall
| Beta: | 0.56 |
| Market Cap (Mil.): | $248,474.09 |
| Shares Outstanding (Mil.): | 2,808.89 |
| Dividend: | 0.66 |
| Yield (%): | 2.98 |
Financials
| JNJ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 24.05 | 35.19 | 35.42 |
| EPS (TTM): | 3.68 | -- | -- |
| ROI: | 10.41 | 19.50 | 18.86 |
| ROE: | 16.28 | 20.27 | 19.73 |
New J&J anti-depressant related to 'Special K' party drug
NEW BRUNSWICK, New Jersey - Johnson & Johnson said it plans to seek approvals for 11 new drugs by 2017, including a treatment for patients with depression who have failed to benefit from standard medications.
UPDATE 4-New J&J anti-depressant related to 'Special K' party drug
NEW BRUNSWICK, N.J., May 23 - Johnson & Johnson said it plans to seek approvals for 11 new drugs by 2017, including a treatment for patients with depression who have failed to benefit from standard medications.
Johnson & Johnson plans on more than 10 drugs filed by 2017
May 23 - Johnson & Johnson said on Thursday that it plans to submit more than 10 new products for regulatory approval by 2017, including drugs to treat hepatitis C, immune diseases, and schizophrenia as well as vaccines for flu, rabies and polio.
FDA approves J&J's Simponi to treat ulcerative colitis
- The Food and Drug Administration has approved Johnson & Johnson's drug Simponi for patients with moderate to severe ulcerative colitis, an inflammatory disease affecting the colon.
UPDATE 1-U.S. FDA approves J&J's Simponi to treat ulcerative colitis
May 15 - The U.S. Food and Drug Administration has approved Johnson & Johnson's drug Simponi for patients with moderate to severe ulcerative colitis, an inflammatory disease affecting the colon.
RPT-U.S. House panel questions resignation of top FDA official
May 13 - A U.S. House of Representatives panel is investigating the circumstances surrounding the resignation from the Food and Drug Administration of its acting deputy commissioner for medical products and tobacco.
House panel questions resignation of top FDA official
- A House of Representatives panel is investigating the circumstances surrounding the resignation from the Food and Drug Administration of its acting deputy commissioner for medical products and tobacco.
U.S. House panel questions resignation of top FDA official
May 13 - A U.S. House of Representatives panel is investigating the circumstances surrounding the resignation from the Food and Drug Administration of its acting deputy commissioner for medical products and tobacco.
Fashion's Betsey Johnson goes to therapy in made-for-TV comeback
LOS ANGELES, May 10 - Mother-daughter therapy, nightly branzino dinners and pulls from a mimosa-filled water bottle at the gym.
FDA approves J&J sedation drug device
- U.S. regulators have approved Johnson & Johnson's Sedasys system to sedate patients during colonoscopies without the need for a physician to monitor delivery of the injectable sedating agent, the company said on Friday.
Competitors
| Price | Change | |
|---|---|---|
| General Electric Company (GE.N) | $23.66 | -0.20 |
| The Procter & Gamble Company (PG.N) | $78.70 | -0.12 |
| Pfizer Inc. (PFE.N) | $29.11 | -0.19 |
| Novartis AG (NOVN.VX) | CHF71.45 | -2.20 |
| Merck & Co., Inc. (MRK.N) | $47.33 | +0.62 |
| Medtronic, Inc. (MDT.N) | $51.46 | -0.07 |
| Baxter International Inc. (BAX.N) | $72.15 | -0.15 |
| Stryker Corporation (SYK.N) | $67.24 | -0.46 |
| Boston Scientific Corporation (BSX.N) | $9.16 | +0.03 |
| Zimmer Holdings, Inc. (ZMH.N) | $79.95 | +0.09 |
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Trading Report for (JNJ). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: ValuEngine, Inc.
|
$127.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
|
Provider: Market Edge
|
$10.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
